The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ...
In our NAP businesses, we recently achieved a key milestone, celebrating our largest service build to date at our Wateridge site, consisting of 26 grams of mRNA material for a preclinical cell and ...
The approval marks the introduction of the first mRNA RSV vaccine in Canada. Credit: MargJohnsonVA via Shutterstock. Moderna has received Health Canada’s approval for its respiratory syncytial virus ...
He added that mRNA vaccine technology, made famous during the Covid-19 pandemic, has a major role in future therapies and is "actually at the heart" of breakthrough therapies like Spinraza and Qalsody ...
When it comes to selecting Cabinet members for President-elect Donald Trump's second term, you can't have too much of a good thing.
A new large study of children in California shows that unvaccinated kids are at a much higher risk of developing multisystem ...
PHILADELPHIA — The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback